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is in agreement with the consensus sequence for N-linked glycosy- 
lation Asn-Xaa-Thr/Ser.
Several lines of evidence indicate that this extra N-glycosyla- 
tion site, created by the mutation, is utilized. A population of 
profibrillin-1 molecules migrating more slowly on SDS-PAGE 
than  the control’s sample was observed in the patient’s sample, Im- 
munohistochemical and ultrastructural analyses revealed that the 
m icro  fibril formation was severely affected in the patient’s fibro­
blast culture. In the presence of tunicamycin, an inhibitor o f  N-gly- 
cosylation, the patient’s cell culture was capable of producing a bet­
te r  organized microfibril network. The creation of a neonatal 
cD N A  construct consisting of exons 24—37 of the FBN1 gene was 
also proven to be a powerful tool in the analyses of the consequences 
o f  this mutation. The polypeptide translated from the minigene 
construct carrying the analogous II048T mutation migrated more 
slowly on SDS-PAGE than the corresponding wild type polypep­
tide. Treatment with either tunicamycin, endoglycosidase H or N- 
glycosidase F abolished the migration difference indicating that 
th e  difference was originally related to the over-N-glycosylation of 
th e  mutant polypeptide.
We conclude that excessive N-glycosylation due to a newly 
form ed N-glycosylation site represents an interesting novel patho­
gen ic  mechanism for Marfan syndrome and should stimulate fur­
th e r  studies.
Grants. The National Marfan Foundation, US
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Neonatal Marfan syndrome is a severe form of the disease usually 
associated with cardiac valvular regurgitation and aortic dilatation 
resulting in death in the first year of life. In addition to the usual 
skeletal and ocular features, flexion contractures, crumpled ears, 
redundant skin and a progeroid facial appearence are not uncom­
m on . The disease may be associated with mutations in exons 
2 3 - 3 2  of the fibrillin gene and with deficient decorin production.
We describe a patient with neonatal Marfan syndrome present­
in g  as a newborn with arachnodactyly, joint laxity, abdominal walL 
laxity, sunken eyes giving a progeroid facial appearance and blue 
sclerae. Iridodonesis was noted at 2 months of age. There were ini­
tia l feeding difficulties and later concerns about poor muscle tone. 
A t  6 months of age, she developed a respiratory infection compli­
ca ted  by recurrent pneumothorax. Emphysematous bullae were 
s e e n  on chest X-ray. The aortic root was dilated. She died from 
respiratory failure 7 days from the onset of symptoms.
In neonatal Marfan syndrome, attention is usually focused on 
th e  cardiovascular abnormalities which often lead to death. How­
e v e r ,  in one literature series, 7/22 patients had respiratory disease. 
R ev iew  of the Aberdeen Marfan Clinic revealed a point prevalence 
o f  Marfan syndrome in North East of Scotland (population 0.5 mil­
lion )  of 1/14000, suggesting reasonably complete ascertainment. 
10 patients were defined as “childhood” cases, being diagnosed at 
u n d e r  18 years o f  age, 2 of 3 sporadic cases in this group (includ­
in g  the subject of this report) suffered recurrent pneumothorax 
w i th  emphysema but none of the 7 familial cases were so affected. 
3 /3 3  adult patients have suffered pneumothorax and a further adult 
h a s  emphysema and pulmonary fibrosis without pneumothorax -  
n o n e  are sporadic cases. Serious lung disease such as pneumotho­
r a x  and emphysema appears to be more common in sporadic child­
hood-diagnosed Marfan syndrome (including neonatal Marfan
syndrome), than in familial adult cases. This may reflect biased as­
certainment o f  severe cases in the sporadic childhood group, but 
could also reflect altered interactions between certain mutated fib­
rillins and other matrix proteins affecting lung integrity. In view of 
the morbidity and potential mortality from lung disease in Marfan 
patients, this area warrants further study.
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Neonatal Marfan syndrome (nMFS) represents the most severe, 
neon at ally lethal form of different Marfan syndrome (MFS) phe­
notypes. Several mutations in nMFS have been detected in the 
fibrillin-1 gene (FBN1). These mutations appear to have clustered 
in a distinct region of FBN1, exons 24-32. These exons code for a 
part of the longest stretch of consecutive EGF-like (epidermal 
growth factor like) motifs in fibrillin polypeptide.
We have constructed a FBN l minigene to study the conse­
quences of different nMFS mutations by in vitro expression. This 
construct contains exons 24-32 of FBNl cDNA inserted into a 
SV-Poly expression vector together with a signal sequence derived 
from a lysosomal enzyme, aspartylglucosaminidase. Several nMFS 
as well as a couple of classical MFS mutations were introduced into 
this minigene using an in vitro mutagenesis kit. For transient trans­
fection COS-1 cells are transfected with different minigenes, then 
pulse-labeled, and medium, cells and ECM are harvested at differ­
ent time-points. Polypeptides are immunoprecipitated with a poly­
clonal antibody and then analyzed on SDS-PAGE and fluorogra- 
pliy. So far, all the mini gens have been shown to be expressed and 
the polypeptides secreted into the medium. Some variation in the 
processing o f  different polypeptides is seen. In some cases the 
polypeptides have also been detected in ECM. We have also set up 
a stable cell line in CHO cells that expresses the wild type mini­
gene. By rotary shadowing electron microscopy we could demon­
strate that these cells produce fibrillin ‘miiiifibers’ that are seen as 
short linear fibrillar structures in cell layers.
Grants . The National Marfan Foundation, US
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Aim of the case report: The Marfan syndrome has a wide variabil­
ity in expression. Symptoms in adults and older children are well 
known but m ay differ from the neonatal Marfan syndrome in 
which serious problems lead to ealry disability and death, espe­
cially cardiac valve insufficiency and pulmonary emphysema.
A full-term newborn girl of a mother with classical Marfan 
syndrome and a father with skeletal findings of Marfan syndrome, 
was admitted one day after birth because of a large diaphragmatic
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hernia in the right thorax. She had the typical marfanoid habitus; 
mitral valve insufficiency (MI); mitral- and tricuspid valve pro­
lapse and aortic diameter > P95,
Bilateral blepharophimosis of the eyelids was an unusual find­
ing. After lateral canthotomy normal eyes were seen. The hernia 
was operated on. At the age of two months a second admission was 
necessary because of severe dyspnea, possibly due to severe MI. 
However, no sings of pulmonary hypertension at heart catheteriza­
tion, no high p C 0 2 level and no pulmonary engorgement on X-ray 
were found. On echo/Doppler cardiography a large left atrium 
with severe Ml was seen. After!oad reduction did not change the 
clinical condition and at; last mitral valve replacement by a St. Jude 
prosthesis was performed. At the time of surgery diffuse pul­
monary emphysema was noted. A short period after surgery the 
patient’s condition improved, but after a respiratory syncytial viral 
infection she died at the age o f  four months. Post mortem in- 
vestiations confirmed severe heart disease and pulmonary emphy­
sema.
Conclusions: be aware of fatal pulmonary emphysema in the 
neonatal Marfan syndrome.
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MICROFIBRILLAR PROTEINS:
THE LONG AND THE SHORT OF IT
J. Rosenbloom
Department of Anatomy and Histology,
University of Pennsylvania School of Dental Medicine,
Philadelphia, PA T9104, USA
Microfibrils having a diameter of 10-12 mn are widely distributed 
in many tissues of the body, often but not always in association 
with elastin. Characterization of the microfibrils remains incom­
plete, but recent findings have suggested that the proteins compos­
ing the microfibrils can be grouped into two classes: (1) large ones 
> 150 kDa and (2) small ones < 50 kDa. The large class contains 
two closely related gene families, the fibrillins (FBNs) and latent 
TGF-p-binding proteins (LTBPs), which share structural domains, 
.including epidermal growth factor and 8-cysteine motifs. Presently, 
two distinct FBNs and three LTBPs are known. Phylogenetic analy­
sis suggests that these two gene families have evolved from a com­
mon ancestral gene. The small class of proteins is more heteroge­
neous and as a group they have been designated microfibril associ­
ated proteins (MFAPs). Sequence analysis has not revealed any 
homology among them. MFAP1 is a 439 amino acid, highly acidic 
protein whose human gene is located near the FBN1 locus, 15ql5- 
q2L MFAP2, previously designated MAGP, is a 183 amino acid 
protein with a wide tissue distribution, whose hum an gene locus is 
Ip36.1-p35. MFAP3 is a 362 amino acid protein whose human 
gene is near the FBN2 locus, 5q21-q31. It is not known whether 
the linkage of Ihese two MFAPs near FBN loci has any functional 
significance or is merely coincidental. Several other glycoproteins 
including emilin and a 36 kDa protein have been localized to the 
microfibrils. While it is likely that the FBNs provide the basic 
scaffolding of the microfibrils, the function of the other proteins is 
unclear. They may stabilize the microfibril structure, interact with 
other matrix components as has been demonstrated for MFAP2 
and elastin and thereby act as nucleation sites in fiber formation, or 
serve as cytokine storage depots as has been suggested for the 
LTBPs.
Grants . NIH grants AR20553 & AR41474.
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Congenital contractural arachnodactyly (CCA) or Beals syndrome 
is an autosomal dominant condition phenotypically related to the 
Marfan syndrome (MFS), We have recently established that CCA 
results from mutations in FBN2, a gene that encodes fibrillin-2 
found in 10-12 nm microfibrils. The previously characterized mu­
tations in unrelated patients were C1252Y in exon 29 and C1433S 
in exon 33. We have subsequently characterized novel FBN2 mu­
tations in three unrelated CCA patients. We identified an exon 29 
splicing error in two affected siblings with unaffected parents. The 
splicing defect is due to an A to G transition at the -15 position in 
the 3' splice site of intron 28. The affected siblings were heterozy­
gous for the mutation. Analysis of the parents’ DNA revealed that 
the father was a somatic mosaic with the mutation present in his 
hair bulb and buccal cells, but not in white blood cells; presum­
ably, the father was also a germline mosaic. Another unrelated 
CCA patient was heterozygous for a mutation resulting in I1092T 
in exon 25. This mutation is not predicted to alter the secondary 
structure of the EGF-like domain encoded by exon 25, but does in­
troduce a novel glycosylation site into the domain, suggesting a 
unique pathogenesis due to this particular mutation. A third puta­
tive mutation in exon 24 (G1056D) was identified in a CCA fam­
ily. We have also identified a family with features of CCA, as well 
as a characteristic facies with hypertelorism, a broad forehead and 
flat facial profile. The phenotype segregates with FBN2 (LOD 
score > 3). These results indicate that FBN2 mutations producing 
CCA are private. The predicted effects of many of the FBN2 mu­
tations on fibrillin-2 are similar to those of FBN 1 mutations. All the 
currently characterized FBN2 mutations occur in a region of the 
gene equivalent to the location of FBN1 mutations that produce 
the severe, neonatal MFS phenotype, Finally, our data suggest that 
FBN2 mutations result in conditions related to CCA.
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Congenital Contractural Arachnodactyly (CCA) is an autosomal 
dominant disorder that is phenotypically similar to, but genetically 
distinct from Marfan syndrome. Genetic linkage analysis impli­
cated the fibrillin-2 gene (FBN2) as the CCA locus. Mutation 
analysis of single CCA patients indicate that defects in FBN2 may 
be responsible for that disorder. However, co-segregation of a mu­
tant allele with the disease phenotype has not been established. We 
have investigated the primary cause of CCA in a large, well char­
acterized kindred with four generations comprising 18 affected in­
dividuals. Previous studies showed linkage of the CCA phenotype
